<DOC>
	<DOC>NCT02180100</DOC>
	<brief_summary>The objectives of this study were to demonstrate comparable safety and efficacy of Terconazole Vaginal Suppositories, 80 mg and fluconazole in the treatment of subjects with severe vulvovaginal candidiasis.</brief_summary>
	<brief_title>Terconazole Vaginal Suppository vs Fluconazole for the Treatment of Severe Vulvovaginal Candidiasis</brief_title>
	<detailed_description>This study were to demonstrate comparable safety and efficacy of Terconazole Vaginal Suppository 80 mg inserted intravaginally once daily before bedtime for 6 consecutive days and oral fluconazole 150mg at day 1 and day 4 in the treatment of subjects with severe vulvovaginal candidiasis.</detailed_description>
	<mesh_term>Candidiasis</mesh_term>
	<mesh_term>Candidiasis, Vulvovaginal</mesh_term>
	<mesh_term>Fluconazole</mesh_term>
	<mesh_term>Terconazole</mesh_term>
	<criteria>Vulvovaginal candidiasis infection is diagnosed, the symptoms evaluated using a numerical rating system based on severity (absent=0; mild=1; moderate=2; severe=3) with a minimum VVC Composite Signs/Symptoms score of 7 Subject completes the informed consent process Subject agrees to take study medication when scheduled Subject complies with all clinical trial instructions. Commits to all followup visits Subject agrees to abstain from sexual intercourse from the time of randomization through the first seven days immediately following treatment had any other sexually transmitted disease or gynaecological abnormality requiring treatment had a disease known to predispose to candidiasis such as diabetes mellitus, or were receiving antibiotics or corticosteriods had used antifungal medication in the week before entry; or were expected to menstruate within seven days of the start of treatment infected more than one candida species</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>48 Years</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>